TY - JOUR T1 - Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis? JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2020-241125 VL - 14 IS - 4 SP - e241125 AU - Sukhraj Singh AU - Zareen Vaghaiwalla AU - Myint Thway AU - Gurjit Singh Kaeley Y1 - 2021/04/01 UR - http://casereports.bmj.com/content/14/4/e241125.abstract N2 - We describe a case of a 48-year-old woman who presented with acute respiratory failure due to diffuse alveolar haemorrhage and acute renal failure due to pauci-immune glomerulonephritis consistent with a new diagnosis of microscopic polyangiitis (MPA). The patient had a recent SARS-CoV-2 infection 6 weeks before MPA diagnosis and had stopped immunosuppression for her rheumatoid arthritis (RA) at that time. The patient was treated with pulse intravenous steroids, plasma exchange therapy and rituximab, which induced remission of her illness. This case highlights a timely dilemma of holding immunosuppression in a RA patient with low disease activity on combination therapy with SARS-CoV-2 infection, and the potential risk of developing an additional autoimmune disease, such as vasculitis, given their existing autoimmunity due to RA. ER -